Recipharm has announced the launch of an integrated OINDP services program called Inhalation Solutions which covers development of MDIs, DPIs, and nasal sprays from early analytical services to scale up and commercial manufacturing.
In June 2018, Recipharm acquired an inhalation manufacturing business in Holmes Chapel, UK from Sanofi. The company also has had inhalation facilities in the US since 2016, when it acquired North Carolina-based Cirrus Pharmaceuticals from Kemwell. Recipharm noted that it has a “dedicated pilot facility composed of several suites which can replicate commercial processes also assists with the seamless transfer of projects from small to large scale production.”
Recipharm Global Key Account Director – Inhalations. Shabbir Mostafa, commented, “Treatments for respiratory conditions are in high demand, making inhalation products a key growth area for our business. In addition to respiratory diseases, they are now being explored as alternative delivery routes to improve bioavailability and lower the risk of adverse effects, in treating for instance central nervous system conditions. This is making inhalation an interesting area for drug developers”.
He added, “The Recipharm team has a long history in inhalation drug product development and manufacturing. This heritage, combined with market demand, made the launch of Recipharm Inhalation Solutions a logical step for us. Our team has the depth of knowledge required to overcome the challenges associated with developing and manufacturing these types of products. We also understand the hurdles on the path to commercialization and are well placed to manage complexity and risk along this journey.”
Read the Recipharm press release.
